Medical device manufacturer Intuitive Surgical (NASDAQ: ISRG) is slated for second-quarter financial results on July 18, Thursday, after the closing bell. Analysts expect the company to report 13.5% growth in revenues to $1.03 billion, riding on strong sales of its da Vinci Surgical Systems.
During the first quarter, the minimally invasive surgery leader shipped 235 da Vinci Surgical Systems, which pushed revenues 15% higher year-over-year.
For the second quarter, Wall Street expects earnings to grow to $2.87 per share, compared to $2.76 per share a year ago. The company will badly want to stay ahead of estimates this time, after missing the street figure in the trailing two quarters. The misses had sent the stock plunging both times.
So far this year, the stock has gained 12.4%, underperforming the S&P500 index’s 19.6% growth.
The Instruments and Accessories is expected to continue its strong growth, after reporting a 20% gain in the last quarter.
The company had a slew of FDA approvals earlier this year. Back in February, ISRG received FDA clearance for its Ion endoluminal system — a robotic-assisted catheter-based platform, designed to navigate through very small lung airways to reach peripheral nodules for biopsies.
In the same month, the company also received FDA approval for the IRIS augmented reality product, designed to aid surgeons in both pre- and intra-operative settings by delivering a 3D image of the patient anatomy.
Then, in March, Intuitive Surgical received FDA clearance for the da Vinci SP Surgical System for use in certain transoral otolaryngology procedures in adults.
Marketing of these products strengthened during the second quarter, which should help lift the results.
ISRG has a 12-month average price target of $568.88, which was at a 9% upside from Wednesday’s trading price. The stock has a Moderate Buy rating, based on nine analysts covering the stock.